Every Form 4 that VolitionRx Limited (VNRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VNRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VNRX filings page.
VolitionRx Ltd. reported a Form 4 showing that Nicholas Plummer, General Counsel of Volition Diagnostics, had 8,146 shares of common stock cancelled on 10/04/2025 to satisfy tax withholding on the settlement of 17,333 restricted stock units (RSUs). The report states no shares were sold by the reporting person or the company; instead, the firm retained shares for cancellation. After the withholding/cancellation, the reporting person beneficially owns 199,731 shares. The reported per-share price tied to the transaction is $0.648.
VolitionRx Ltd (VNRX) insider tax-withholding share cancellation
The company reported that on 10/04/2025 12,333 shares of common stock were disposed of under Transaction Code F at a reported price of $0.648 per share. The filing explains these shares represent the portion of 24,666 restricted stock units settled for the reporting person that were retained by VolitionRx for cancellation to satisfy tax-withholding obligations. The reporting person, Gaetan Michel, is listed as Chief Operating Officer and a director; the form states that no shares were sold by the reporting person or by VolitionRx in connection with this withholding arrangement.
VolitionRx Ltd. reporting person Jacob Vincent Micallef, Chief Scientific Officer and director, reported a non‑derivative transaction on 10/04/2025 that reduced his direct common stock holdings by 5,850 shares at a price of $0.648 per share. The form states these 5,850 shares represent the portion of shares retained by the company to satisfy tax withholding upon settlement of 13,000 restricted stock units (RSUs); no shares were sold by the reporting person. After the transaction he beneficially owns 393,089 shares directly, plus 55,000 shares held by his spouse and 38,113 shares held by Borlaug Limited, a company he controls. The filing is informational and documents insider ownership and the tax‑withholding mechanics tied to RSU settlement.
Rodney Gerard Rootsaert, a reporting officer and director of VolitionRx Ltd (VNRX), reported a transaction dated 09/28/2025 involving restricted stock units. To satisfy tax withholding on the settlement of 9,900 restricted stock units, VolitionRx retained 4,158 common shares (transaction code F) at an indicated per-share price of $0.605; no open-market sale occurred. After the withholding, the reporting person beneficially owns 145,075 shares directly. In addition, Concord International, Inc. holds 1,007,718 shares indirectly; Rootsaert is a controlling director of Concord and shares voting and dispositive control. The Form 4 indicates shares were retained by the company for tax withholding and clarifies ownership forms but does not show any derivative transactions.
Salvatore Thomas Butera, listed as an officer (CEO - Volition Veterinary) and director of VolitionRx Ltd (VNRX), reported transactions dated 09/28/2025 on a Form 4. The filing shows 5,230 shares of common stock disposed of at $0.605 per share by means of share retention by the issuer to satisfy tax withholding on the settlement of 19,125 restricted stock units; the filing states no shares were sold by the reporting person or the company. The reporting person beneficially owns 332,285 shares following the transaction, and 99,350 shares are jointly owned with his spouse.
Jacob Vincent Micallef, Chief Scientific Officer and director of VolitionRx Ltd (VNRX), reported a Section 16 transaction dated 09/28/2025. The filing shows 5,568 shares of common stock disposed at $0.605 per share under transaction code F. The filer states these shares were retained by VolitionRx to satisfy tax withholding obligations on the settlement of 12,375 restricted stock units, and explicitly notes that no shares were sold by the reporting person or VolitionRx in that transaction.
Following the reported transaction, the reporting person beneficially owns 398,939 shares directly, plus 55,000 shares held indirectly by spouse and 38,113 shares held by Borlaug Limited (the reporting person is the controlling director of Borlaug Limited with voting and dispositive control). The form is a routine insider disclosure of ownership changes related to equity compensation tax withholding.
Ann-Louise Batchelor, Group Chief Marketing Officer of VolitionRx Ltd (VNRX), reported a transaction dated 09/28/2025 on Form 4 in which 5,604 shares of common stock were disposed of under code F at a price of $0.605 per share. The filing shows 154,282 shares beneficially owned directly after the transaction and 29,406 shares indirectly beneficially owned through her spouse.
The filing explanation states these 5,604 shares represent the portion of 11,925 restricted stock units whose shares were retained by VolitionRx and cancelled to satisfy the reporting person’s tax withholding obligations upon settlement. The form clarifies that no shares were sold by the reporting person or by VolitionRx in connection with the withholding.
VolitionRx insider filing: Michel Gaetan, the company's Chief Operating Officer and a director, reported a transaction dated 09/28/2025 reducing his direct common stock holding. The Form 4 shows a Code F disposition of 11,362 shares at $0.605, leaving 369,079 shares beneficially owned directly after the reported transaction. The filing explains these 11,362 shares represent the portion of 22,725 restricted stock units retained by VolitionRx to satisfy tax withholding upon settlement; the form states no shares were sold by the reporting person or the company in the process. The form is signed by Gaetan on 09/30/2025.
Gael Forterre, Chief Commercial Officer and reporting person for VolitionRx Ltd (VNRX), reported a transaction dated 09/28/2025 that reduced his direct common stock holdings by 5,503 shares at a price of $0.605 per share. The filing explains these 5,503 shares were retained by the issuer to satisfy tax withholding obligations upon settlement of 13,725 restricted stock units; no shares were sold by Mr. Forterre or VolitionRx. After the reported transaction he beneficially owns 160,924 shares directly, plus 5,000 shares held by his spouse and 32,500 shares managed by Armorica Partners, LLC, for which he is the managing director and sole shareholder.